Topical Antibiotics in Orthopedic Surgeries



Laura Certain, MD, PhD
Clinical Associate Professor, Infectious Diseases
Adjunct Associate Professor, Orthopaedics
October 3, 2023

Disclosures

None

Acknowledgements

- Adam Kantor, MD content and references
- Jeremy Gililland, MD spacer pictures

Types and routes of topical antibiotics

- Bone cement (polymethylmethacrylate = PMMA)
- Powder placed directly into the surgical site
- Calcium sulfate beads (Stimulan)
- Intra-osseous

Bone cement


Three purposes:

- Fix prostheses in place
- Deliver local antibiotics
- Fill dead space

Mostly used in:

- Arthroplasty
 - Prevention and treatment of PJI (periprosthetic joint infection)
- Trauma
 - Treatment of infected fractures, chronic osteomyelitis

Spacers can be all cement and static.



More often, patients have "articulating" spacers



Curr Rev Musculoskelet Med. 2015; 8(4): 373–382.

Or can have a more durable "spacer."





Antibiotic cement elutes for a long time.

- 49 patients undergoing two-stage exchange with spacer placement
- Synovial fluid concentration measured at the time of the second surgery

Time Between Stages (d)	Tobramycin Level (mg/L)	Vancomycin Level (mg/L)
≤60	6.88 (3.33–10.43)	2.28 (1.68-2.88)
61-90	8.66 (6.09-11.24)	1.95 (1.22-2.56)
91-130	4.35 (3.36-5.35)	1.49 (1.03-1.95)
>130	1.98 (1.32-1.98)	0.97 (0.77-1.17)

Serum concentrations persist as well

- 21 patients undergoing two-stage exchange with spacer placement
- Serum antibiotic concentration measured weekly

	Vancomycin μg/mL Mean (SD)		Tobramycin μg/mL Mean (SD)
	On IV Vancomycin	Not on IV Vancomycin	
Week 1	18.70 (3.45)	14.38 (0.94)	0.27 (0.10)
Week 2	16.17 (5.86)	13.10 (11.34)	0.35 (0.08)
Week 3	16.35 (4.58)	7.76 (7.73)	0.41 (0.18)
Week 4	13.26 (5.76)	7.21 (8.61)	0.39 (0.14)
Week 5	13.08 (6.24)	7.89 (7.77)	0.32 (0.21)
Week 6	15.55 (2.46)	6.05 (8.64)	0.38 (0.15)
Week 7	8.35 (6.66)	1.80 (0.94)	0.30 (0.20)
Week 8	21.50 (0)	7.53 (8.04)	0.59 (0.58)

Edelstein. 2018. Journal of Arthroplasty 33(3): 835-839

Typical antibiotics in bone cement

- Vancomycin + gram negative agent
- Tobra and gent most commonly
- Can also add antifungals (vori, ampho)

- Total amount typically ≤15% (≤ 2g per 40 g of cement)
- Elution kinetics depend on cement viscosity

U of U Hip/Knee Protocol

Standard antimicrobials used in cement	Amount per 40 g cement	Typical dose for infected joints at stage 1 (spacer placement)	Typical dose for infected joints at stage 2 (permanent prosthesis)
Vancomycin	≤ 2 g	2 g	1 g
Ceftazidime	≤ 4 g	3 g	2 g
OR			
Tobramycin	≤ 3.6 g	3.6 g	1.2 g

TABLE 1. Available antibiotics and anti-fungals which can be used in spacers


Antibiotic Group	Type of Antibiotic	Activity Against	Dose per 40 gm cement (in grams)
Aminoglycoside	Tobramycin	Gram-negative bacteria such as Pseudomonas	1 to 4.8
Aminoglycoside	Gentamicin	Gram-negative bacteria-Escherichia coli, Klebsiella and particularly Pseudomonas aeruginosa. Also aerobic bacteria (not obligate/facultative anaerobes)	o.25 to 4.8
Cephalosporin, 1st gen	Cefazolin	Gram-positive infections, limited gram-negative coverage	1 to 2
Cephalosporin, 2nd gen	Cefuroxime	Reduced gram-positive coverage, improved gram-negative coverage	1.5 to 2
Cephalosporin, 3rd gen	Ceftazidime	Gram-negative bacteria, particularly Pseudomonas	2
Cephalosporin, 4th gen	Cefotaxime	Gram-negative bacteria, no activity against Pseudomonas	2
Cephalosporin, 5th gen	Ceftaroilne	Gram-negative bacteria, no activity against Pseudomonas	2 to 4
Fluoroquinolone	Ciprofloxacin	Gram-negative organisms including activity against Enterobacteriaciae	0.2 to 3
Glycopeptide	Vancomycin	Gram-positive bacteria, including methicillin-resistant organisms	0.5 to 4
Lincosamide	Clindamycin	Gram-positive cocci, anaerobes	1 to 2
Macrolide	Erythromycin	Aerobic gram-positive cocci and bacilli	0.5 to 1
Polymyxin	Colistin	Gram-negative	0.24
β-lactam	Piperacillin- not available Piptzobactam	ilable Enterobacteria and anaerobes	
β-lactam	n Aztreonam Only gram-negative bacteria		4
β-lactamase inhibitor	tamase inhibitor Tazobactam Gram-negative bacteria (particularly <i>Pseudomonas</i>), Enterobacteria, and anaerobes in combination with Piperacillin		0.5
Oxazolidinones	Linezolid	Multidrug-resistant gram-positive cocci such as MRSA	1.2
Carbapenem	Meropenem	Gram-positive and gram-negative bacteria, anaerobes, Pseudomonas	0.5 to 4
Lipopeptide	Daptomycin	Only gram-positive organisms	2
Antifungale	Amphotericin	Most fungi	200
Antifungal	Voricanazole	Most fungi	300-600 mg

Intra-wound antibiotics

- Usually vancomycin powder
- Sometimes Gram negative agent added (gent, tobra, ceftaz)
- Most evidence comes from the spine surgery literature

First study of topical vancomycin – 2009

• Retrospective cohort study, Sweet et al.



Two meta-analyses in 2019 both showed a benefit.

The effect of prophylactic vancomycin powder on infections following spinal surgeries: a systematic review

Vincent Dodson, Neil Majmundar, Vanessa Swantic, Rachid Assina

> Neurosurg Focus. 2019 Jan 1;46(1):E11. doi: 10.3171/2018.10.FOCUS18470.

Selection pressures of vancomycin powder use in spine surgery: a meta-analysis


```
Abhiram Gande <sup>1</sup>, Alex Rosinski <sup>2</sup>, Torin Cunningham <sup>3</sup>, Nitin Bhatia <sup>4</sup>, Yu-Po Lee <sup>4</sup>

Meta-Analysis > Spine J. 2019 Jun;19(6):1076-1084. doi: 10.1016/j.spinee.2019.01.002.

Epub 2019 Jan 17.
```

Also studied in tibia fracture – VANCO study

• Prospective RCT in 34 trauma centers (O'Toole et al. 2021)



Dissolvable beads (calcium sulfate)

- Only purpose is to deliver antibiotics locally
 - Generally used by trauma surgeons for infected fracture fixation
- Any antibiotic can be mixed in
 - Vanc, gent, rifampin most common
- Dissolve over days to weeks
 - Can cause wound drainage

Intra-osseous antibiotics

- Newer idea in the prosthetic joint infection literature
- Typically vancomycin (500 mg) or cefazolin (1 g)
- Injected into the tibial plateau (for knees) after the tourniquet is inflated

Clin Orthop Relat Res (2021) 479:2504-2512 DOI 10.1097/CORR.000000000001919 Clinical Orthopaedics and Related Research® A Publication of The Association of Bone and Joint Surgeons

Clinical Research

Intraosseous Regional Prophylactic Antibiotics Decrease the Risk of Prosthetic Joint Infection in Primary TKA: A Multicenter Study

Ben Parkinson MBBS, FRACS (Orth), FAOrthA¹⁻³, Peter McEwen MBBS, FRACS (Orth), FAOrthA²⁻⁴, Matthew Wilkinson MBBS, FRACS (Orth), FAOrthA²⁻⁴, Kaushik Hazratwala MBBS, FRACS (Orth), FAOrthA²⁻⁴, Jorgen Hellman B.med, FRACS (Orth), FAOrthA⁵, Heng Kan MBBS¹, Andrew McLean MBBS¹, Yash Panwar MBBS⁵, Kenji Doma PhD, BSpExcSci(Hons), MClinExPhys(Rehab), CSCS, AEP, NSCAM, ESSAM²⁻³, Andrea Grant BSpExSci²